Data published in Journal of Pharmacology and Experimental Therapeutics NodThera’s brain-penetrant NLRP3 inhibitors matched weight loss driven by GLP-1 receptor agonist semaglutide (Wegovy®) or calorie

BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc.,

Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering

• Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNH• Majority of patients remained transfusion

•“CDLK5 Forum Award for Excellence – Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London•First-in-class

Edinburgh and Cambridge, UK, – Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA at Independent Non-Executive

BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces that the first patients have been

Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S.